GlaxoSmithKline Net Income 2006-2018 | GSK

GlaxoSmithKline annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • GlaxoSmithKline net income for the quarter ending September 30, 2018 was $1.848B, a 16.44% increase year-over-year.
  • GlaxoSmithKline net income for the twelve months ending September 30, 2018 was $2.833B, a 7.02% decline year-over-year.
  • GlaxoSmithKline annual net income for 2017 was $1.974B, a 59.74% increase from 2016.
  • GlaxoSmithKline annual net income for 2016 was $1.236B, a 90.4% decline from 2015.
  • GlaxoSmithKline annual net income for 2015 was $12.877B, a 175.99% increase from 2014.
GlaxoSmithKline Annual Net Income
(Millions of US $)
2017 $1,974
2016 $1,236
2015 $12,877
2014 $4,666
2013 $8,807
2012 $7,520
2011 $8,757
2010 $2,865
2009 $8,877
2008 $8,741
2007 $10,433
2006 $10,133
2005 $8,770
GlaxoSmithKline Quarterly Net Income
(Millions of US $)
Q3 2018 $1,848
Q2 2018 $600
Q1 2018 $1,063
Q4 2017 $-678
Q3 2017 $1,587
Q2 2017 $-230
Q1 2017 $1,296
Q4 2016 $395
Q3 2016 $1,061
Q2 2016 $-624
Q1 2016 $404
Q4 2015 $-541
Q3 2015 $834
Q2 2015 $228
Q1 2015 $12,248
Q4 2014 $1,556
Q3 2014 $648
Q2 2014 $1,114
Q1 2014 $1,123
Q4 2013 $3,924
Q3 2013 $1,566
Q2 2013 $1,605
Q1 2013 $1,466
Q4 2012 $1,370
Q3 2012 $1,807
Q2 2012 $1,981
Q1 2012 $2,139
Q4 2011 $1,972
Q3 2011 $2,191
Q2 2011 $1,802
Q1 2011 $2,442
Q4 2010 $-1,116
Q3 2010 $2,082
Q2 2010 $-427
Q1 2010 $2,056
Q4 2009 $2,724
Q3 2009 $2,251
Q2 2009 $2,262
Q1 2009 $1,681
Q4 2008 $1,495
Q3 2008 $2,496
Q2 2008 $2,600
Q1 2008 $2,635
Q4 2007 $2,194
Q3 2007 $2,720
Q2 2007 $2,690
Q1 2007 $2,995
Q4 2006 $2,309
Q3 2006 $2,691
Q2 2006 $2,461
Q1 2006 $2,684
Q4 2005 $2,019
Q3 2005 $2,237
Q2 2005 $2,162
Q1 2005 $2,322
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $100.041B $38.892B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $391.677B 18.36
Pfizer (PFE) United States $259.009B 14.60
Merck (MRK) United States $205.072B 17.77
Novartis AG (NVS) Switzerland $203.357B 17.38
AbbVie (ABBV) United States $137.681B 12.22
Eli Lilly (LLY) United States $120.583B 21.20
Sanofi (SNY) France $113.115B 14.01
Novo Nordisk (NVO) Denmark $107.931B 17.53
AstraZeneca (AZN) United Kingdom $103.013B 12.79
Bristol-Myers Squibb (BMY) United States $88.253B 14.53